Sera Prognostics, Inc. (SERA)
After hours:
| Previous close | 8.38 |
| Open | 8.36 |
| Bid | 8.22 x 400 |
| Ask | 8.29 x 100 |
| Day's range | 8.13 - 8.43 |
| 52-week range | 1.52 - 12.35 |
| Volume | |
| Avg. volume | 189,287 |
| Market cap | 269.72M |
| Beta (5Y monthly) | 1.34 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
SERA PROGNOSTICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the first quarter of 2024 ended March 31, 2024.
- PR Newswire
Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2024 Financial Results on May 8, 2024
Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report first quarter fiscal year 2024 financial results on Wednesday, May 8, 2024, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time
- PR Newswire
SERA PROGNOSTICS REPORTS FOURTH QUARTER 2023 FINANCIAL RESULTS
Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the fourth quarter and full year ended December 31, 2023.
